|Post IPO Valuation|
|Venture Round, 4/2010 |
Hercules Technology Growth Capital
PolyMedix, Inc., a development stage biotechnology company, focuses on treating acute cardiovascular disorders and infectious diseases with synthetic small molecule compounds that mimic the activity of large natural protein molecules. The company, using its proprietary computational drug design technology, created heparin antagonist compounds, defensin mimetic antibiotic compounds, and other drug compounds for human therapeutic use. Its developing products include PMX-60056, a heptagonist compound to reverse the activity of both heparin and low molecular weight heparins, which is under phase IB clinical trial; and PMX-30063, a broad spectrum IV antibiotic that is under phase IB clinical trial. The companyâ€™s pre clinical stage products include PMX-30063, a broad spectrum antibiotic for oral and topical applications; PMX-50003 and PMX-70004 polymer biomaterials; PMX-10072, an anti-tuberculosis compound; and PMX-30024, an anti-malaria compound. PolyMedix, Inc.â€™s pre-clinical stage products also include PMX-10098, an anti-fungal compound; PMX-30016, a bio-defense product; and PMX-2005, an angiogenesis inhibitor. The company was founded in 2002 and is based in Radnor, Pennsylvania.